SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?


To: Louis A. Rawden who wrote (29329)10/14/1999 11:00:00 AM
From: Cacaito  Read Replies (1) | Respond to of 32384
 
Collateral,but very important: NEJM-Accutane-Neuroblastoma.

Very good results for children with neuroblastoma adding Accutane (retinoic therapy)on 3 year follow up of more than 500 patients.

It is strong evidence for retinoids as anticancer agents.

Ligand's products should be able to mimic and improve on Accutane findings.